AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a GBX 5,800 ($75.71) target price on the biopharmaceutical company’s stock. Jefferies Group’s price objective suggests a potential upside of 13.46% from the stock’s current price.

Several other equities research analysts have also recently issued reports on AZN. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a report on Wednesday, May 25th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a report on Friday, May 27th. Deutsche Bank AG restated a “buy” rating and issued a GBX 5,600 ($73.10) target price on shares of AstraZeneca plc in a report on Tuesday, May 31st. JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 3,900 ($50.91) target price on shares of AstraZeneca plc in a report on Tuesday, May 31st. Finally, Goldman Sachs Group Inc. set a GBX 3,700 ($48.30) price target on shares of AstraZeneca plc and gave the stock a “sell” rating in a research report on Tuesday, May 31st. Five equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. AstraZeneca plc presently has an average rating of “Hold” and a consensus target price of GBX 4,926.80 ($64.31).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 5136.00 on Wednesday. The company has a 50-day moving average of GBX 5,021.00 and a 200 day moving average of GBX 4,348.66. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s market capitalization is GBX 64.97 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/astrazeneca-plcs-azn-buy-rating-reiterated-at-jefferies-group.html

The business also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were issued a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.